TY  - GEN
AU  - Cure,H
AU  - Souteyrand,P
AU  - Ouabdesselam,R
AU  - Roche,H
AU  - Ravaud,A
AU  - D'incan,M
AU  - Viens,P
AU  - Fargeot,P
AU  - Lentz,M A
AU  - Fumoleau,P
AU  - Hanauske,A
AU  - Chollet,P
TI  - Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group
SN  - 0960-8931
PY  - 2000///0229
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Combined Modality Therapy
KW  - Dacarbazine
KW  - therapeutic use
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Nitrosourea Compounds
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1097/00008390-199912000-00011
ER  -